Agenus Inc. - Special Call Transcript
Hi, everyone, and welcome to our first R&D update, which is coined Agenus Insights.
There's never been a more important time in the history of cancer therapy. Technology, partnered with genomic and proteomic insights have accelerated our pace of drug discovery to speeds that have never been seen before. Agenus is at the forefront of this, with more than 15 new discoveries advancing in the clinic in just the past 4 years. A few of those first agents are in route to BLA with filings already underway.
Our anti-PD-1 is delivering differentiated activity compared to commercially available PD-1 antibodies. And 1181, our Fc-engineered anti-CTLA-4, we presented a data update yesterday, and that molecule is producing very exciting results in difficult-to-treat tumors.
Now TIGIT, the topic of our conversation today. It's shaping up as the next breakthrough target in I-O. And only as recently as last year, anti-CTLA-4 and anti-PD-1 were the only validated immunotherapy combinations for patients with cancer. Today, this third pathway
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
